Shanghai Fosun Pharmaceutical : ANNOUNCEMENT - ON COMPLETION OF THE ISSUANCE OF THE FIRST TRANCHE SUPER SHORT-TERM COMMERCIAL PAPER FOR 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ɪऎూ݋ᔼᖹ€ණྠٰ΅Ϟࠢʮ̡

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT

ON COMPLETION OF THE ISSUANCE OF THE FIRST TRANCHE SUPER SHORT-TERM

COMMERCIAL PAPER FOR 2021

Reference is made to the announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") dated 28 May 2020 (the "Announcement") in relation to the Notice of Acceptance for Registration (Zhong Shi Xie Zhu [2020] No. SCP325) issued by the Association on 19 May 2020 regarding the acceptance of the registration of the super short-term commercial paper. The registered amount of the registered paper is RMB5 billion, which is effective for two years commencing from 19 May 2020, and issuable in tranches within the Effective Registration Period. Unless otherwise specified, capitalized terms used herein shall have the same meaning as ascribed to them in the Announcement.

The Company has recently completed the issuance of the first tranche of super short-term commercial paper for 2021 (the "Current Tranche of Super Short-term Commercial Paper") within the above registered amount. The results of the issuance of Current Tranche of Super Short-term Commercial Paper are set out below:

Name of the Current Tranche of Super Short-term Commercial Paper	The First Tranche of Super Short-term Commercial Paper of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. for 2021* (ɪऎూ݋ᔼᖹ€ණྠٰ΅Ϟࠢʮ ̡2021ϋܓୋɓಂ൴೵ಂፄ༟Վ)
Short Name of the Current Tranche of Super Short-term Commercial Paper	21 Fosun Pharma SCP001* (21 ూ݋ᔼᖹ SCP001)	Code of the Current Tranche of Super Short-term Commercial Paper	012100715
Aggregate principal amount	RMB1.5 billion	Term of the Current Tranche of Super Short-term Commercial Paper	90 days
Method of interest calculation	Repayment of the principal and interest in lump sum at fixed rate on maturity
Nominal value per unit	RMB100	Coupon rate	3.10%
Value date	26 February 2021	Payment date	27 May 2021
Leading underwriter	China CITIC Bank Corporation Limited
Joint leading underwriter	Bank of Shanghai Co., Ltd.

The relevant documents in relation to the Current Tranche of Super Short-term Commercial Paper have been published on the website of China Money athttp://www.chinamoney.com.cnand the website of

Shanghai Clearing House athttp://www.shclearing.com.

This announcement does not constitute, or form part of, an offer or invitation, or solicitation or inducement of an offer, to subscribe for or purchase the Current Tranche of Super Short-term Commercial Paper or any of other securities of the Company, nor is this announcement circulated to invite offers for any securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, PRC

26 February 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* for identification purposes only